Besides anti-TWEAK antibodies, Tigatuzumab, a humanized version of the agonistic murine monoclonal antibody TRA-8, directed against TRAIL, another member of the TNF ligand superfamily, is under investigation in patients with pancreatic cancer [29], highlighting the therapeutic potential of these ligands. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.